Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Novartis Venture Fund
BioCentury | Jan 31, 2025
Finance
Versant, Orbimed lead $65M launch of GIP-focused start-up Helicore
In BioCentury’s Venture Report: Oncomatryx, Quibin raise cash in Spain; Atalanta draws $97M; Forbion’s BioEconomy Fund
BioCentury | Dec 13, 2024
Finance
Techbio VC Dimension upsizes for $500M second fund; PE firm takes stake in Andera
In BioCentury’s Venture Report: Fundings for Citryll, Angitia, Tasca, Veradermics and more
BioCentury | Oct 3, 2024
Finance
Kurma investing new fund; Kailera advancing obesity assets with $400M
BioCentury’s latest Venture Report also features news about LoQus23, Aktis, Resolution, Triveni, Flagship and more
BioCentury | Jul 31, 2024
Management Tracks
Murray joins Bioluminescence
Plus: Terns names Elona Kogan chief legal officer, and updates from AiCuris and Anaveon
BioCentury | Jul 18, 2024
Finance
Venture Report: Five biotechs raise nearly $800M in two-day flurry
Plus: New capital for CytoReason, Truvian and Renalys
BioCentury | Jun 28, 2024
Finance
Venture Report: Curie.Bio’s fund; megarounds for Formation, EvolutionaryScale, BillionToOne
Plus: New fundings for Exsilio, TwoStep and Augustine
BioCentury | Feb 21, 2024
Management Tracks
Phil Pang exiting Vir as CMO
Plus: Arshad Khanani named chief medical adviser at Opthea and Smart Immune names a chair
BioCentury | Feb 7, 2024
Management Tracks
Verily names Myoung Cha as chief product officer
Plus: New CFO for Innovent and updates from Takeda, Shionogi, Lexeo, Stuart, Arcellx and more
BioCentury | Oct 14, 2023
Emerging Company Profile
AstronauTx: targeting astrocytes to treat neurodegenerative diseases
London, U.K.-based company aims to clear a wide array of toxic proteins out of the brain, and is settings it first sights on Alzheimer’s disease
BioCentury | Oct 10, 2023
Emerging Company Profile
Hyku: tapping new targets by taking chemoproteomics beyond cysteine
In co-leading Hyku’s $56M seed round, RA Capital added to its portfolio of chemoproteomics companies
Items per page:
1 - 10 of 286